Biotech News
Related news
PCVXVaxcyte2026-03-18 23:34 EST
Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate
PCVXVaxcyte2026-09-03 20:05 EST
Vaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected VAX-31 OPUS-1 Topline Data
VXRTVaxart2026-02-18 13:00 EST
Vaxart to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026
VXRTVaxart2026-09-08 12:00 EST
Vaxart to Present at the H.C. Wainwright 28th Annual Global Investment Conference
GSKGSK plc2026-01-07 12:00 EST
GSK’s Shingrix (Recombinant Zoster Vaccine) prefilled syringe presentation approved by the European Commission
GSKGSK plc2025-10-21 07:05 EST
GSK’s Shingrix new prefilled syringe presentation receives positive CHMP opinion
Vaxcyte
Carrier-Sparing Vaccine Platform Vaxcyte develops broad-spectrum conjugate vaccines using a platform designed to include more bacterial antigens without overloading the carrier proteins needed to generate immune responses. Adult VAX-31 Program VAX-31 is a 31-valent pneumococcal conjugate vaccine in Phase 3 development for adults. The...
Recent company news
PCVXVaxcyte2026-09-03 20:05 EST
Vaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected VAX-31 OPUS-1 Topline Data
PCVXVaxcyte2026-08-27 20:05 EST
Vaxcyte to Participate in Upcoming Investor Conferences
PCVXVaxcyte2026-08-05 20:05 EST
Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update
PCVXVaxcyte2026-07-08 20:05 EST
Vaxcyte to Participate in Upcoming Investor Conferences
PCVXVaxcyte2026-06-02 20:05 EST
Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults
Stock data
- Close
- 58.92 USD
- Market cap
- 6.85B USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States